Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.469, 2005-01, pp. : 13-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
New trimetazidine formulation benefits clinical, QOL status
Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. :
Access to resources
Recommend
Exemestane: clinical benefits without QOL compromise
Inpharma, Vol. 1, Iss. 1530, 2006-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. :
Natalizumab shows clinical, cost and QOL benefits
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 514, 2006-01 ,pp. :
. . . and also shows QOL benefits
Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. :